While TLR3/TLR4-TRIF activation drives the progression of drug-induced liver injury, ischemia-reperfusion liver injury, and autoimmune hepatitis, TRIF exhibits a dual role in ALD and MASLD/MASH. The gene discussed is TICAM1; the disease is metabolic dysfunction-associated steatotic liver disease.